Janux Therapeutics Stock Hits 52-Week Low After Trial Update

Janux Therapeutics Stock Hits 52-Week Low After Trial Update

JANX stock hit 52-week low after releasing Phase 1 data for JANX007 in mCRPC. Encouraging efficacy and safety profile observed in trials. Latest Ratings for JANX Date Firm Action From To Jul 2021 B of A Securities Initiates Coverage On Buy Jul 2021 Cowen & Co. Initiates Coverage On Outperform Jul 2021 HC Wainwright & Co. Initiates Coverage On Buy View More Analyst Ratings for JANX View the Latest Analyst Ratings read more